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all GERD patients. CONCLUSION: Partial responders to PPI
treatment are more costly and score lower on physical and
mental dimensions of HRQoL than patients responding well to
PPI treatment and GERD patients in general.
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OBJECTIVES: This study aims to examine whether the test-
retest reliability of SF-36, WHOQOL-BREF, and EQ-5D
questionnaires will be changed by different administration
approaches by which patients with chronic liver disease self-
report their quality of life. METHODS: Patients with chronic
liver disease were recruited from the outpatient department of a
medical centre in Taiwan. Their self-reported questionnaires
were collected by two approaches. The ﬁrst approach patients
received was an interview and questionnaire in hospital. They
returned the retest questionnaire by mail two weeks later. In the
second approach, patients were instructed to ﬁll out both test and
retest questionnaires at home and send back by two separate
mails. The time gap was also two weeks. After scoring question-
naires, a paired-t test was conducted to compare test-retest
reliability for three questionnaires. The mean score difference
between two approaches was examined by independent t test.
An analyses of mean score differences of different domains
were performed by multiple linear regressions. RESULTS: Of 69
patients recruited for the ﬁrst approach; 52 persons completed
both questionnaires (75%), while the response rate of the second
approach was 84% (127 of 151). The results indicate that there
is no statistically signiﬁcant difference in the test-retest reliability
of SF-36, WHOQOL-BREF, and EQ-5D questionnaires. There
was also no signiﬁcant difference in the test-retest results between
two approaches, except in the dimension ‘pain/discomfort’ mean
difference (0.3  1.2 and -0.1  1.1, p = 0.03) by EQ-5D.
Similar results (p = 0.04) were also found by multiple linear
regression, after controlling age, sex, and education. This reﬂects
that greater pain/discomfort was more likely to present in the
ﬁrst approach as compared to that in the second one. CONCLU-
SIONS: Alternative administration approaches did affect the
results of test-retest questionnaires, which idicated that the
Hawthorne Effect occurred in the interview in hospital.
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OBJECTIVE: Current GERD assessment questionnaires for
adults are limited in their ability to capture nocturnal symptoms.
The objective of this study was to develop and validate an instru-
ment to assess severity and impact of nocturnal GERD symp-
toms. METHODS: Two focus groups and 16 cognitive debrieﬁng
interviews were conducted among patients with GERD to iden-
tify key issues and concerns related to nocturnal GERD symp-
toms. The resulting 29-item draft instrument was included in a
study of 196 patients diagnosed with GERD at 12 clinics in the
United States to evaluate the psychometric properties. Assess-
ments were conducted at baseline and at 4 weeks. Construct
validity was evaluated using the Patient Assessment of Upper
Gastrointestinal Disorders Symptoms Questionnaire (PAGI-
SYM), Patient Assessment of Upper Gastrointestinal Disorders-
Quality of Life (PAGI-QOL), number of nights with symptoms,
disability days, and clinician and patient assessment of GERD
severity. Exploratory factor analyses and item response theory
analyses were conducted to ﬁnalize items and subscales.
RESULTS: Mean age of participants was 45 years; 76% were
female and 68% were Caucasian. Patient-rated severity at base-
line was mild or moderate for 69% of participants, with 48%
reporting GERD-related symptoms 2–3 nights within the past
week. The ﬁnal questionnaire includes 20 items and consists of 3
subscales: nocturnal symptoms; morning impact; and concern
regarding nocturnal GERD. The subscales demonstrated internal
consistency reliability (Cronbach’s alpha 0.92–0.95). The sub-
scale scores were statistically signiﬁcantly correlated with sub-
scales of the PAGI-SYM and PAGI-QOL (0.41–0.81; all
p < 0.0001), number of nights with GERD symptoms (0.45–
0.54; all p < 0.0001), disability days (0.19–0.43; all p < 0.05),
and clinician and patient-reported disease severity (0.46–0.72; all
p < 0.0001). CONCLUSION: Results support the reliability and
validity of the newly developed questionnaire as a measure of
severity of nocturnal GERD symptoms, morning impact, and
concern related to nocturnal GERD.
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OBJECTIVE: To determine the prevalence and severity of
constipation among persons receiving hospice care in the
United States, using longitudinal patient-reported outcomes.
METHODS: Data was obtained from excelleRx, Inc, a national
hospice pharmacy. Patient-reported symptom outcome data were
collected by telephone for each patient by trained research assis-
tants within the ﬁrst three days of hospice admission. Data
collection continued every three to four days until patients were
discharged, or unable or unwilling to report data or dead.
Patients rated constipation on a four-point verbal rating scale of
none, mild, moderate, and severe. The sample for our analysis
came from ﬁve participating hospices and included all discharged
or deceased patients receiving home hospice care with an admis-
sion assessment record and at least one subsequent telephone
assessment for constipation between April 1, 2006 and October
20, 2007. The ﬁrst patient reported constipation assessment
score post hospice admission was used to estimate prevalence
and severity of constipation. RESULTS: A total of 309 patients
met the inclusion criteria, the majority of which were female
(n = 167, 54%), Caucasian (n = 282, 91%), >65 years of age
(n = 238, 77%) and had a primary diagnosis of cancer (n = 223,
72%). All patients were prescribed opioid therapy during their
hospice experience. Constipation was reported at the ﬁrst assess-
ment post admission by 26% of the patients (n = 80), 28.7 % of
patients with cancer (n = 64) and 18.6% of patients without
cancer (n = 16). Most patients who reported constipation were
female (58.8%) and >65 years (78.8%). Constipation intensity
was rated as mild (n = 32; 40%), moderate (n = 23; 28.8%)
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